Cathepsin A (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Cathepsin A (CTSA; UniProt P10619), expressed in HEK293 cells. Suitable for carboxypeptidase activity assays, β-galactosidase/neuraminidase stabilisation studies, inhibitor screening, and antibody validation.
Expression system
HEK293
Cat. #
REC-CathepsinA

In stock

SKU
REC-CathepsinA
$498.00

Target Overview

Cathepsin A (gene: CTSA; UniProt P10619) is a 480-amino-acid lysosomal serine carboxypeptidase (EC 3.4.16.5) that serves a dual role in the lysosome: it functions as a carboxypeptidase capable of deamidating tachykinins, and it acts as a structural chaperone essential for the stability and enzymatic activity of lysosomal β-galactosidase and neuraminidase-1 (NEU1). Without Cathepsin A, both β-galactosidase and NEU1 are rapidly degraded within the lysosomal compartment, underscoring its role as a protective protein rather than merely a hydrolase. This recombinant is expressed in HEK293 mammalian cells, a system that supports the glycosylation and disulfide-bond formation necessary for correct folding and biological activity of this heavily post-translationally modified enzyme. HEK293-derived material is therefore preferred over bacterial or insect-cell preparations when native-like carboxypeptidase activity or chaperone-competent protein conformation is required. Researchers use this recombinant in several experimental contexts: measuring carboxypeptidase activity against synthetic fluorogenic substrates, reconstituting the Cathepsin A/β-galactosidase/NEU1 multienzyme complex in cell-free systems, screening small-molecule inhibitors for IC50 determination, and characterising substrate specificity with tachykinin peptides. It also serves as a positive-control antigen in Western blot and immunohistochemistry validation workflows. Investigators requiring orthogonal antibody validation can pair this recombinant with the matched Triple Point Biologics antibody (SKU: RP-CathepsinA), which has been validated for Western blot against human CTSA. Species reactivity of the antibody is validated for human and predicted for mouse, rat, non-human primate, and dog, consistent with the high sequence conservation of CTSA across mammals.

Background

Cathepsin A (CTSA; also designated lysosomal protective protein, PPCA, carboxypeptidase C, or carboxypeptidase L) is a serine carboxypeptidase of the prolyl oligopeptidase family that resides in the lysosome. Its biology is notable for the combination of two biochemically distinct functions in a single polypeptide: (1) a carboxypeptidase activity that cleaves C-terminal amino acids from substrates including the neuropeptides substance P and endothelin, and (2) a non-enzymatic chaperone/protective function that is required for the lysosomal stability and catalytic activity of β-galactosidase and the sialidase NEU1. The trimeric complex formed by Cathepsin A, β-galactosidase, and NEU1 is sometimes referred to as the lysosomal multienzyme complex (LMC), and Cathepsin A is regarded as the structural core that recruits and stabilises the other components. Loss-of-function variants in CTSA cause galactosialidosis, a lysosomal storage disorder characterised by the co-deficiency of β-galactosidase and neuraminidase. Related disorders — GM1-gangliosidosis, Gaucher disease, and Niemann-Pick disease type C — involve disruption of closely associated lysosomal hydrolase networks, and Cathepsin A's role in that network has made it a research target in the broader lysosomal storage disorder field. A recent study using patient-specific midbrain organoids with CRISPR correction to model neuronopathic Gaucher disease (Lin Y et al., eLife, 2026; PMID 42334452) illustrates how researchers are now using organoid and gene-editing tools to probe the lysosomal hydrolase system, providing a cellular context in which recombinant Cathepsin A can serve as a biochemical reference standard. Beyond lysosomal storage biology, CTSA is being characterised in the context of pulmonary arterial hypertension, where defects in lysosomal enzyme trafficking have been reported (Xiao G et al., Front Cardiovasc Med, 2026; PMID 42257032), and in studies of age-dependent variability in lysosomal hydrolase expression relevant to small-molecule drug metabolism (Gadara D et al., Clin Pharmacol Ther, 2026; PMID 42198901). The NEU1-activating function of Cathepsin A has also attracted interest in the context of sialidase-dependent receptor signalling, as NEU1 modulates cell-surface sialylation of multiple receptors. For in vitro research, recombinant Cathepsin A expressed in mammalian cells provides a well-folded, glycosylated enzyme suitable for activity assays, multienzyme complex reconstitution, inhibitor profiling, and as an antigen standard for antibody characterisation workflows.

Applications

  • Carboxypeptidase activity assay using fluorogenic or chromogenic C-terminal substrate analogues (e.g., Z-Phe-Ala-based substrates)
  • Inhibitor IC50 determination for small-molecule serine carboxypeptidase inhibitors
  • In vitro reconstitution of the Cathepsin A / β-galactosidase / NEU1 lysosomal multienzyme complex
  • NEU1 sialidase activation assay — recombinant Cathepsin A used to assess NEU1 stimulation in cell-free conditions
  • Tachykinin (substance P / endothelin) deamidation and C-terminal processing assay
  • Positive-control antigen for Western blot validation of anti-CTSA antibodies (pairs with SKU RP-CathepsinA)
  • Immunohistochemistry standard for titrating anti-Cathepsin A antibody signal in tissue sections
  • Binding/pull-down assay to study protein–protein interactions within the lysosomal protective protein complex

References

  1. Lin Y et al. Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies. Elife. 2026. doi:10.7554/eLife.109518. PMID: 42334452.
  2. Mahmoudi A et al. Exploring the Potential of Calebin-A in Targeting Obesity-Related Genes and Pathways. J Cell Mol Med. 2026. doi:10.1111/jcmm.71244. PMID: 42286733.
  3. Xiao G et al. Defect in lysosomal enzyme trafficking and sorting is associated with irreversibility of pulmonary arterial hypertension. Front Cardiovasc Med. 2026. doi:10.3389/fcvm.2026.1763556. PMID: 42257032.
  4. Yao Z et al. The Prognostic Value of Serum Interleukin-6 Concentrations for 9 Cardiovascular and Mortality Outcomes: The Cross Cohort Collaboration (CCC). J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.04.015. PMID: 42201287.
  5. Gadara D et al. Characterization of Lysosomal Hydrolases and Transporters and Their Age-Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs. Clin Pharmacol Ther. 2026. doi:10.1002/cpt.70341. PMID: 42198901.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Lysosome

Frequently Asked Questions

What molecular weight does recombinant Cathepsin A run at on SDS-PAGE or Western blot?

The CTSA gene encodes a 480-amino-acid precursor (~54 kDa unmodified), but HEK293-expressed Cathepsin A undergoes N-linked glycosylation and proteolytic processing into a two-chain mature form (a ~32 kDa heavy chain and a ~20 kDa light chain linked by a disulfide bond). Under reducing SDS-PAGE conditions expect two bands near 32 and 20 kDa; under non-reducing conditions the disulfide-linked heterodimer migrates closer to 54–58 kDa. Glycosylation typically adds 4–8 kDa above theoretical mass, so exact migration can vary slightly by lot.

Is this recombinant Cathepsin A the mature processed form or the zymogen precursor?

The HEK293-expressed material is the mature, processed form. Cathepsin A is synthesized as a 54 kDa single-chain precursor that undergoes lysosomal cleavage to yield the active heavy-chain/light-chain heterodimer. Our recombinant is supplied as this processed, enzymatically active species — not the uncleaved zymogen — making it suitable for carboxypeptidase activity assays and chaperone-function studies without requiring an additional activation step.

What substrate and assay conditions should I use to measure recombinant Cathepsin A carboxypeptidase activity?

Cathepsin A (EC 3.4.16.5) is most commonly assayed using the fluorogenic substrate Z-Phe-Ala-AMC or the chromogenic substrate Cbz-Phe-Ala-pNA, both cleaved at the C-terminal amide or ester bond. A typical assay buffer is 100 mM sodium acetate pH 5.0, 150 mM NaCl — reflecting the acidic lysosomal optimum. Monitor fluorescence at Ex/Em 360/460 nm (AMC release) or absorbance at 405 nm. Start with 20–50 nM recombinant Cathepsin A and 200 µM substrate; titrate substrate from 25–500 µM to determine Km. Include 1 mM PMSF inhibition control to confirm serine-carboxypeptidase-dependent signal.

What buffer is recombinant Cathepsin A supplied in, and does it interfere with downstream assays?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. Glycerol at 10% is generally enzyme-protective and does not inhibit carboxypeptidase activity at typical working dilutions (1:10 to 1:50 into assay buffer). Note that Cathepsin A activity is optimal near pH 5.0; diluting into sodium acetate assay buffer drops glycerol carry-over below 1%, which is well tolerated. If studying chaperone interactions with β-galactosidase or NEU1, the neutral-pH storage buffer is preferable, as both partner enzymes are unstable below pH 6.5.

What starting concentration of recombinant Cathepsin A should I use for an in vitro chaperone protection assay with NEU1 or β-galactosidase?

Published protection assays (e.g., Bonten et al.) typically use a 1:1 to 5:1 molar ratio of Cathepsin A to partner enzyme (NEU1 or β-galactosidase) in a lysosomal-mimic buffer (50 mM sodium acetate pH 4.5–5.0, 150 mM NaCl) at 37 °C for 30–60 min. A practical starting point is 200–500 nM Cathepsin A with 100 nM partner enzyme. Confirm partner enzyme stability by measuring residual activity (β-galactosidase: MUG substrate, Ex/Em 365/450 nm; NEU1: 4-MU-NANA substrate) after incubation with and without Cathepsin A.

Can I use recombinant Cathepsin A as a positive control on Western blot with the RP-CathepsinA antibody?

Yes — this is a primary use case for pairing REC-CathepsinA with RP-CathepsinA. Load 50–100 ng of recombinant Cathepsin A per lane under reducing conditions; the heavy-chain (~32–36 kDa, glycosylated) and light-chain (~20 kDa) bands should both be detected by RP-CathepsinA. The antibody was raised against a recombinant antigen from the same expression platform, so epitope recognition is reliable. Use the recombinant lane alongside your cell or tissue lysate to confirm band identity and calibrate exposure. See /anti-cathepsin-a-rabbit-polyclonal-antibody for recommended antibody dilutions.

How much recombinant Cathepsin A should I load for Western blot if I'm validating the RP-CathepsinA antibody?

For antibody validation purposes, a two-point titration works well: load 25 ng and 100 ng of REC-CathepsinA on the same gel alongside your sample lysate. This demonstrates linearity and confirms the antibody detects both the ~32 kDa heavy chain and ~20 kDa light chain (reducing conditions). If running non-reducing conditions, expect a single heterodimeric band at ~54–58 kDa. RP-CathepsinA is validated for Western blot at the dilution ranges listed on the antibody page (/anti-cathepsin-a-rabbit-polyclonal-antibody); use a standard HRP-conjugated secondary against rabbit IgG.

How should I store and handle recombinant Cathepsin A to maintain activity, and what is its shelf life?

Upon receipt, spin briefly to collect contents, then aliquot into single-use volumes to avoid repeated freeze-thaw, which progressively denatures the disulfide-linked heterodimer and reduces carboxypeptidase activity. Store aliquots at -20 °C; do not store at 4 °C long-term. When thawing, keep on ice and use within 4 hours. Shelf life is 12 months from date of receipt under recommended storage. Dilutions in assay buffer should be prepared fresh; carrier protein (0.1% BSA) can be added to stabilize dilute working stocks below 10 nM. Avoid detergents other than 0.01% Tween-20 in working buffers.

Validation imagery coming soon

Western blot validation figures for REC-CathepsinA will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →